Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD
Author(s) -
Eveline Bruinstroop,
Rinkoo Dalan,
Yang Cao,
Yong Mong Bee,
Kurumbian Chandran,
Li Wei Cho,
Shui Boon Soh,
Eng Kiong Teo,
SueAnne Toh,
Melvin KheeShing Leow,
Rohit A. Sinha,
Suresh Anand Sadananthan,
Navin Michael,
Heather M. Stapleton,
Christopher Leung,
Peter Angus,
Sheila K. Patel,
Louise M. Burrell,
Su Chi Lim,
Chee Fang Sum,
S. Sendhil Velan,
Paul M. Yen
Publication year - 2018
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2018-00475
Subject(s) - levothyroxine , medicine , euthyroid , endocrinology , thyroid , nonalcoholic fatty liver disease , steatosis , fatty liver , diabetes mellitus , hormone , gastroenterology , type 2 diabetes mellitus , body mass index , disease
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and associated with significant morbidity and mortality. Thyroid hormone (TH) increases β-oxidation of fatty acids and decreases intrahepatic lipid content (IHLC) in rodents with NAFLD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom